Company Overview of Amorcyte, LLC
Amorcyte, LLC develops and manufactures cell therapy products for the treatment of cardiovascular diseases. Its product includes AMR-001, a bone marrow-derived, CD34 positive selected stem cell product for the prevention of major adverse cardiac events following acute myocardial infarction. The company was incorporated in 2005 and is based in Allendale, New Jersey. As of October 17, 2011, Amorcyte, LLC operates as a subsidiary of Caladrius Biosciences, Inc.
4 Pearl Court
Allendale, NJ 07401
Founded in 2005
Key Executives for Amorcyte, LLC
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Amorcyte, LLC, please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.